118 related articles for article (PubMed ID: 23842228)
21. Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition.
Kerner GS; Koole MJ; Bongaerts AH; Pruim J; Groen HJ;
PLoS One; 2016; 11(5):e0149955. PubMed ID: 27137772
[TBL] [Abstract][Full Text] [Related]
22. Lung cancer: Resolving resistance to ALK-targeted therapy.
Hutchinson L
Nat Rev Clin Oncol; 2016 Feb; 13(2):64. PubMed ID: 26806320
[No Abstract] [Full Text] [Related]
23. ALK gene amplified in most inflammatory breast cancers.
Tuma RS
J Natl Cancer Inst; 2012 Jan; 104(2):87-8. PubMed ID: 22215853
[No Abstract] [Full Text] [Related]
24. Targeted therapies: new standard for ALK-positive NSCLC.
Hutchinson L
Nat Rev Clin Oncol; 2015 Feb; 12(2):66. PubMed ID: 25560531
[No Abstract] [Full Text] [Related]
25. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C
Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
[TBL] [Abstract][Full Text] [Related]
26. ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?
Vergne F; Quéré G; Andrieu-Key S; Descourt R; Quintin-Roué I; Talagas M; De Braekeleer M; Marcorelles P; Uguen A
Lung Cancer; 2016 Jan; 91():67-9. PubMed ID: 26603857
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer.
Pender A; Popat S
Ther Adv Respir Dis; 2015 Jun; 9(3):97-104. PubMed ID: 25801645
[TBL] [Abstract][Full Text] [Related]
28. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
29. An update of ALK inhibitors in human clinical trials.
Chan EL; Chin CH; Lui VW
Future Oncol; 2016 Jan; 12(1):71-81. PubMed ID: 26618223
[TBL] [Abstract][Full Text] [Related]
30. Treatment and detection of ALK-rearranged NSCLC.
Peters S; Taron M; Bubendorf L; Blackhall F; Stahel R
Lung Cancer; 2013 Aug; 81(2):145-54. PubMed ID: 23769207
[TBL] [Abstract][Full Text] [Related]
31. Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.
Peled N; Zach L; Liran O; Ilouze M; Bunn PA; Hirsch FR
J Thorac Oncol; 2013 Dec; 8(12):e112-3. PubMed ID: 24389447
[No Abstract] [Full Text] [Related]
32. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
Cappuzzo F; Moro-Sibilot D; Gautschi O; Boleti E; Felip E; Groen HJ; Germonpré P; Meldgaard P; Arriola E; Steele N; Fox J; Schnell P; Engelsberg A; Wolf J
Lung Cancer; 2015 Feb; 87(2):89-95. PubMed ID: 25576294
[TBL] [Abstract][Full Text] [Related]
33. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ
J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824
[No Abstract] [Full Text] [Related]
34. Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.
Toyokawa G; Hirai F; Inamasu E; Yoshida T; Nosaki K; Takenaka T; Yamaguchi M; Seto T; Takenoyama M; Ichinose Y
J Thorac Oncol; 2014 Dec; 9(12):e86-7. PubMed ID: 25393798
[No Abstract] [Full Text] [Related]
35. ALK-targeted therapy for lung cancer: ready for prime time.
Husain H; Rudin CM
Oncology (Williston Park); 2011 Jun; 25(7):597-601. PubMed ID: 21888258
[TBL] [Abstract][Full Text] [Related]
36. A functional landscape of resistance to ALK inhibition in lung cancer.
Wilson FH; Johannessen CM; Piccioni F; Tamayo P; Kim JW; Van Allen EM; Corsello SM; Capelletti M; Calles A; Butaney M; Sharifnia T; Gabriel SB; Mesirov JP; Hahn WC; Engelman JA; Meyerson M; Root DE; Jänne PA; Garraway LA
Cancer Cell; 2015 Mar; 27(3):397-408. PubMed ID: 25759024
[TBL] [Abstract][Full Text] [Related]
37. [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
Girard N
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S96-9. PubMed ID: 26118885
[TBL] [Abstract][Full Text] [Related]
38. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
[TBL] [Abstract][Full Text] [Related]
39. Crizotinib: an anaplastic lymphoma kinase inhibitor.
Gadgeel SM; Bepler G
Future Oncol; 2011 Aug; 7(8):947-53. PubMed ID: 21823889
[TBL] [Abstract][Full Text] [Related]
40. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
Bowles DW; Weickhardt AJ; Doebele RC; Camidge DR; Jimeno A
Drugs Today (Barc); 2012 Apr; 48(4):271-82. PubMed ID: 22536569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]